Antibody-Conjugated CIDEs for BRM Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemical inducers of degradation (CIDEs) face challenges with targeted delivery and stability, leading to short half-life and low bioavailability, which limits their effectiveness in protein degradation therapies.
Innovation Solution
Development of antibody-conjugated CIDEs (Ab-CIDEs) with tailored linker structures to enhance potency, stability, and solubility, where antibodies direct CIDEs to target cells, facilitating intracellular protein degradation through the ubiquitin-proteasome pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional CIDEs are used for protein degradation, then protein degradation activity is achieved, but targeted delivery is poor and stability is low
Solution Approach 1:
The patent combines the CIDE molecule with an antibody through conjugation, creating an Ab-CIDE construct. This merging provides the stability and targeted delivery of antibodies with the protein degradation capability of CIDEs, resolving the contradiction between stability and complexity by integrating two functional components into a unified therapeutic agent.
Solution Approach 2:
The Ab-CIDE construct represents a composite molecular system combining protein (CIDE) and antibody components. This composite structure leverages the pharmacokinetic advantages of antibodies (stability, half-life) while retaining the degradation function of CIDEs, effectively improving reliability without excessive complexity.
2Duration of action of moving object
If conventional CIDEs are used, then protein degradation function is provided, but half-life is short and bioavailability is low
Solution Approach 1:
By conjugating CIDE with antibody, the construct inherits the long half-life and improved bioavailability characteristics of antibodies. This merging of components directly addresses the short half-life limitation of conventional CIDEs while maintaining the degradation function.
Solution Approach 2:
The antibody acts as an intermediary carrier that protects the CIDE from rapid clearance and facilitates prolonged circulation. This intermediary role of the antibody resolves the half-life issue by mediating the pharmacokinetic properties of the overall construct.
3Ease of operation
If CIDE size is reduced to improve delivery, then delivery efficiency may improve, but stability and potency are compromised
Solution Approach 1:
The construct is segmented into distinct functional modules: the antibody portion for targeted delivery and the CIDE portion for protein degradation. This segmentation allows each component to optimize its function while working together, improving delivery efficiency without sacrificing potency.
Solution Approach 2:
Different regions of the Ab-CIDE construct have specialized functions: the antibody region provides targeted binding and delivery properties, while the CIDE region maintains degradation potency. This local quality differentiation resolves the contradiction by allowing each segment to be optimized for its specific role.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Ab-CIDEs effectively target and degrade BRM proteins, demonstrating improved potency and stability, potentially leading to effective treatments for related diseases by modulating protein activity and extending therapeutic benefits.
Implementation Method 1
One of the cell's major degradation pathways is known as the ubiquitin-proteasome system. In this system, a protein is marked for degradation by the proteasome by ubiquitinating the protein. The ubiqutinization of the protein is accomplished by an E3 ubiquitin ligase that binds to a protein and adds ubiquitin molecules to the protein.
Implementation Method 2
The E3 ubiquitin ligase is part of a pathway that includes E1 and E2 ubiquitin ligases, which make ubiquitin available to the E3 ubiquitin ligase to add to the protein.
Data Source
AI summary
The subject matter described herein is directed to antibody-CIDE conjugates (Ab-CIDEs) that target BRM for degradation, to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where BRM degradation is beneficial.